Welcome to the 7th International Neoantigen Summit!
There has been a huge wave of interest and investment in neoantigen therapies, for instance, CureVac has collaborated with Lilly to build mRNA-based cancer vaccines as well as Nykode Therapeutics has shown promising immunogenicity results in their phase 1/2a study.
Join Directors, Heads, VPs, and C-Level executives in Cancer Vaccines, Bioinformatics, Immunotherapies and Translational Immunology at the 7th International Neoantigen Summit. This meeting consists of 3 jam-packed days of industry dedicated content from 25+ world-class speakers to stay ahead of the curve and overcome challenges of accurate target prediction and successful translation into the clinic for the acceleration of more immunogenic therapeutics and vaccines towards the patients in need.
What Will You Learn?
Delve into the latest advances in bioinformatic tools and machine learning techniques towards accurate prediction of neoantigen targets to unlock more immunogenic therapies with CureVac & Epitopea
Hear novel and brand-new clinical data insights to stay ahead of the curve and fast-track your neoantigen-based therapies towards approval with Gritstone Bio, Geneos Therapeutics & Imvax
Drive the success of personalised medicines by addressing the challenges of turnaround time, cost and tumour heterogeneity with Nykode Therapeutics & BlueSphere Bio
Improve your combination strategy by gaining a better understanding of the mechanism of action for novel combination therapies for more effective treatment of solid tumours with Precision Biologics, Inc. & Replicate Bioscience
Leverage innovative delivery platforms and vaccine design for more targeted neoantigen vaccines towards the patients in need with Valo Therapeutics & Nouscom Srl
Key Event Features:
A global speaker faculty, showcasing content from top Biopharma from across the neoantigen community
Unmissable agenda sessions showcasing the latest and greatest advances in biopharma, from target identification and validation to preclinical and clinical content
Unparalleled networking opportunities to meet the entire global neoantigen community under one roof
Your opportunity to meet and source innovative partners to help overcome your key challenges and drive neoantigen therapy success